Current androgen-deprivation therapy (ADT) is initially effective at reducing AR signalling and PC progression, but most patients inevitably become resistant to these treatments via multiple mechanisms including AR gene amplification and through AR splice variants (1). The gene discussed is AR; the disease is pachyonychia congenita.